Rallybio CorporationRLYBNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank33
3Y CAGR-21.6%
5Y CAGR+2.1%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
-21.6%/yr
Annual compound
5Y CAGR
+2.1%/yr
Recent deceleration
Percentile
P33
Within normal range
vs 5Y Ago
1.1x
Modest growth
Streak
2 yr
Consecutive declineContracting
PeriodValueYoY Change
2025$19.60M-52.8%
2024$41.51M-22.5%
2023$53.54M+31.6%
2022$40.69M+51.2%
2021$26.91M+52.6%
2020$17.63M+55.1%
2019$11.37M-